VWD type 2N (Normandy) in two sisters
J. L. Agne
Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA
Search for more papers by this authorN. Ahmad
Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Search for more papers by this authorJ. E. Palascak
Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Search for more papers by this authorR. Khaled
Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Search for more papers by this authorCorresponding Author
N. A. Karim
Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Correspondence: Nagla Abdel Karim, MD, Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Tel.: +513 558 2115; fax: + 513 558 2124;
e-mail:[email protected]
Search for more papers by this authorJ. L. Agne
Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA
Search for more papers by this authorN. Ahmad
Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Search for more papers by this authorJ. E. Palascak
Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Search for more papers by this authorR. Khaled
Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Search for more papers by this authorCorresponding Author
N. A. Karim
Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Correspondence: Nagla Abdel Karim, MD, Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Tel.: +513 558 2115; fax: + 513 558 2124;
e-mail:[email protected]
Search for more papers by this author
References
- 1Philipp CS, Faiz A, Dowling N et al. Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol 2005; 105: 61–6.
- 2Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423–8.
- 3Rodeghiero R, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454–9.
- 4Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 485–9.
- 5Gaucher C, Jorieux S, Mercier B, Oufkir D, Mazurier C. The, “Normandy” variant of von Willebrand disease: characterization of a point mutation in the von Willebrand factor gene. Blood 1991; 77: 1937–41.
- 6Michiels J, Berneman Z, Gadisseur A et al. Classification and characterization of hereditary Types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease. Clin Appl Thromb Hemost 2006; 12: 397–420.
- 7Michiels J, van de Velde A, van Vliet H, van der Planken M, Schroyens W, Berneman Z. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost 2002; 28: 111.
- 8Michiels J, van Vliet H, Berneman Z et al. Intravenous DDAVP and Factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients with von Willebrand disease type 1, 2 and 3. Clin Appl Thromb Hemost 2007; 13: 14–34.
- 9Michiels J, Berneman Z, Planken M, Schroyens W, Budde U, Vliet H. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII – von Willebrand factor concentrate (Haemate-P). Blood Coagul Fibrinolysis 2004; 15: 323–30.
- 10Castaman G, Bertoncello K, Bernardi M, Rodeghiero F. Pregnancy and delivery in patients with homozygous and heterozygous R854Q type 2N von Willebrand disease. J Thromb Haemost 2005; 3: 391–2.